Patients Rising Now appreciates the opportunity to provide our comments on ICER’s May 4th
draft evidence report, “Elagolix for Treating Endometriosis.”
Patient perspectives about endometriosis are complicated. The pain and personal consequences
of endometriosis (e.g., infertility, pain with intercourse), are very challenging to evaluate and
treat. ICER’s draft report, in part because it evaluates one unapproved potential therapy, contains
limited data on real-world effectiveness, as well as critical patient factors and perspectives,
which raises numerous concerns about the draft report. Our patient-focused comments about this
report are below, organized into sections about Patient Perspectives and Complexity, Cost
Considerations and Analyses, and Technical Notes.